SPOTLIGHT: ARYx slashes IPO price

ARYx Therapeutics (a 2004 Fierce 15 company) raised $50 million in its IPO after slashing its price from a forecasted $14 to $16 a share down to $10. Report

Suggested Articles

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me

Q32 Bio is working on treatments for autoimmune and inflammatory diseases that improve on systemic approaches.